[Pubmed] Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: a case report
Posté : 30 mai 2024 12:00
Ther Adv Neurol Disord. 2024 May 28;17:17562864241254895. doi: 10.1177/17562864241254895. eCollection 2024.
ABSTRACT
Myasthenia gravis (MG) is an autoimmune disorder characterized by fluctuating muscle weakness. Severe patients may develop life-threatening respiratory failure and experience crisis. Plasma exchange or intravenous immunoglobulin (IVIg) is the first-line treatment option for myasthenia crisis, but some patients still poorly respond to them. Here, we first reported a generalized MG patient from China who was in a state of impending myasthenic crisis and did not respond effectively to IVIg but was successfully rescued by add-on efgartigimod. Especially, we also detected meaningful changes in T-cell and B-cell subsets after efgartigimod, promoting a potential role of efgartigimod in re-establishing immune homeostasis.
PMID:38813520 | PMC:PMC11135074 | DOI:10.1177/17562864241254895
Source: https://pubmed.ncbi.nlm.nih.gov/3881352 ... t9+e462414